Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CFTR | P13569 | 2/20 | 0.50 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587111 | 0.85 | ALDH1A1 (0.61) | ALDH1A1HPGDKDM4EGAACFTR | |
| SCHEMBL3588982 | 0.83 | ALDH1A1 (0.56) | ALDH1A1HPGDKDM4EGAALMNA | |
| SCHEMBL8219165 | 0.80 | ALDH1A1 (0.55) | ALDH1A1HPGDKDM4EGAACFTR | |
| SCHEMBL13502539 | 0.78 | KDM4E (0.59) | ALDH1A1HPGDKDM4EGAALMNA | |
| SCHEMBL13502461 | 0.75 | CYP1A2 (0.54) | ALDH1A1GAALMNAP2RX4MAPK1 | |
| SCHEMBL1966502 | 0.72 | PKM (0.64) | ALDH1A1HPGDKDM4EGAACFTR | |
| SCHEMBL1965210 | 0.71 | KDM4E (0.61) | ALDH1A1HPGDKDM4EGAALMNA | |
| SCHEMBL14006985 | 0.71 | ALDH1A1 (1.00) | ALDH1A1HPGDKDM4EGAALMNA | |
| SCHEMBL1963901 | 0.70 | CFTR (0.66) | ALDH1A1HPGDKDM4EGAALMNA | |
| SCHEMBL982925 | 0.70 | CFTR (0.58) | ALDH1A1HPGDKDM4EGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061764-B1 | HETEROCYCLIC DERIVATIVES BINDING TO THE PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR (PBR) | TECHNION RES & DEV FOUNDATION (IL) | 2014-07-02 | — | — | EP | disclosed |
| US-8541428-B2 | Heterocyclic derivatives, pharmaceutical compositions and methods of use thereof | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2013-09-24 | — | — | US | disclosed |
| US-8541428-B2 | Heterocyclic derivatives, pharmaceutical compositions and methods of use thereof | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2013-09-24 | — | — | US | disclosed |
| EP-2589597-A2 | Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (PBR) | Technion Research & Development Foundation (IL) | 2013-05-08 | — | — | EP | disclosed |
| US-20100029658-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2010-02-04 | — | — | US | disclosed |
| US-20100029658-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029658-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | NQO1, SIRT5, KEAP1 | ALDH1A1 2459/4885HPGD 103/4885KDM4E 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.